Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease

BACKGROUND: Immunotherapy for Alzheimer’s disease(AD) has gained momentum in recent years. One of the concerns over its application pertains to Cost-Effectiveness Analysis (CEA) from population average and specific subgroup differences, as such a therapy is imperative for health decision-makers to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chung-Hsien, Fann, Jean Ching-Yuan, Chen, Sam Li-Sheng, Chen, Hsiu-Hsi, Yang, Kuen-Cheh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791033/
https://www.ncbi.nlm.nih.gov/pubmed/31195946
http://dx.doi.org/10.2174/1567205016666190612162121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791033/
https://www.ncbi.nlm.nih.gov/pubmed/31195946
http://dx.doi.org/10.2174/1567205016666190612162121

Ejemplares similares